Evidence map›Paper›PMID 41656970›Full record

ArticleInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2026

Modified tumor uptake and biodistribution of nanoparticles coated with small extracellular vesicle membranes derived from distinct tumor cell lines.

Samir V Jenkins, Hayden Carlton, Bree Scott, Shelbie D Stahr, Whit Vinson, Gabriel Fletcher, Azemat Jamshidi-Parsian, Ping-Ching Hsu, Ruud P M Dings, David Huitink and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Samir V JenkinsDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Hayden CarltonDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-2249-3067
Bree ScottDepartment of Mechanical Engineering, University of Arkansas, Fayetteville, AR, USA.
Shelbie D StahrDepartment of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Whit VinsonDepartment of Mechanical Engineering, University of Arkansas, Fayetteville, AR, USA.
Gabriel FletcherDepartment of Mechanical Engineering, University of Arkansas, Fayetteville, AR, USA.
Azemat Jamshidi-ParsianDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Ping-Ching HsuDepartment of Environmental Health Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Ruud P M DingsDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID 0000-0001-7686-1331
David HuitinkDepartment of Mechanical Engineering, University of Arkansas, Fayetteville, AR, USA.
Robert J GriffinDepartment of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID 0000-0002-3574-2958

Funding

The Role o f Tetrahydrobiopterin (BH4) Bioavailability in Radiation-induced Skin InjuryP20GM109005 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI BOERMA, MARJAN · 2015 to 2024
$21.1M
Pilot Grant ProgramP30GM145393 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI MARK S SMELTZER · 2022 to 2026
$7.6M
Improvement of cellular immunotherapy during dysbiosis- ResubmissionR01CA245083 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI DINGS, RUUD P.M. · 2021 to 2025
$1.9M
NCI NIH HHS R01 CA245083NIGMS NIH HHS P20 GM109005NIGMS NIH HHS P30 GM145393
6 · The paper itself

Abstract

backgroundTargeting tumors with nanoparticles can significantly improve the anti-tumor effect of thermal treatments while sparing normal tissue from nonspecific effects. The surface coating is essential to driving the biological fate of nanomaterials. Exosomes, a type of long-circulating secreted vesicle, are capable of specific cell targeting and present a variety of molecules on the surface.

methodsDifferences among physiochemical properties and protein expression of the exosome isolates were quantified based on the origin of the exosomes. Extrusion through polycarbonate membranes was used to coat nanoparticles with these membranes. TEM was used to visualize cell uptake

resultsIn vivo The exosome coating promoted particle immunoevasion and accumulation in different organs, though it limited extravasation within the tumor as well, independent of the source cell line. TEM of individual tumor cells showed that particles with exosome coating are taken up more rapidly than uncoated particles and these particles accumulate in multivesicular bodies. Particles were incubated

conclusionsSignificant changes in biodistribution, cellular uptake, and heating induced by alternating magnetic field were observed with these formulations. Studies are ongoing to identify the proteins needed to maximize tumor accumulation and efficacy of thermal therapy.

Indexed as

ExosomesExtracellular VesiclesNanoparticlesAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CTissue Distributionbiodistributionexosomemagnetic heatingMagnetic nanoparticletumor targeting

Identifiers

PMID41656970
PMCPMC13004575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.